ATE239492T1 - Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen - Google Patents

Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen

Info

Publication number
ATE239492T1
ATE239492T1 AT00905696T AT00905696T ATE239492T1 AT E239492 T1 ATE239492 T1 AT E239492T1 AT 00905696 T AT00905696 T AT 00905696T AT 00905696 T AT00905696 T AT 00905696T AT E239492 T1 ATE239492 T1 AT E239492T1
Authority
AT
Austria
Prior art keywords
treatment
medication
produce
heart disease
bpi protein
Prior art date
Application number
AT00905696T
Other languages
English (en)
Inventor
Brett P Giroir
Patrick J Scannon
Original Assignee
Xoma Technology Ltd
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd, Univ Texas filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE239492T1 publication Critical patent/ATE239492T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751Bactericidal/permeability-increasing protein [BPI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00905696T 1999-01-22 2000-01-21 Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen ATE239492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11673699P 1999-01-22 1999-01-22
PCT/US2000/001515 WO2000043028A2 (en) 1999-01-22 2000-01-21 Method of treating chronic cardiac disease

Publications (1)

Publication Number Publication Date
ATE239492T1 true ATE239492T1 (de) 2003-05-15

Family

ID=22368911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905696T ATE239492T1 (de) 1999-01-22 2000-01-21 Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen

Country Status (11)

Country Link
US (3) US6509317B1 (de)
EP (1) EP1143996B1 (de)
JP (2) JP2002535282A (de)
CN (1) CN1353614A (de)
AT (1) ATE239492T1 (de)
AU (1) AU778001B2 (de)
CA (1) CA2359681A1 (de)
DE (1) DE60002552T2 (de)
MX (1) MXPA01007031A (de)
NZ (1) NZ513087A (de)
WO (1) WO2000043028A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
US20110002893A1 (en) * 2008-11-03 2011-01-06 Ut-Battelle, Llc Diagnosis and treatment of congenital heart defects using nell1
US9974759B2 (en) * 2013-05-31 2018-05-22 Indiana University Research And Technology Corporation Beta 2 adrenoceptor antagonists for treating orthostatic hypotension
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643875A (en) 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5578568A (en) 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia

Also Published As

Publication number Publication date
DE60002552D1 (de) 2003-06-12
JP2007126479A (ja) 2007-05-24
CA2359681A1 (en) 2000-07-27
US20060171937A1 (en) 2006-08-03
CN1353614A (zh) 2002-06-12
EP1143996B1 (de) 2003-05-07
DE60002552T2 (de) 2004-02-26
US7045501B2 (en) 2006-05-16
NZ513087A (en) 2003-02-28
US6509317B1 (en) 2003-01-21
WO2000043028A2 (en) 2000-07-27
WO2000043028A3 (en) 2000-11-30
AU2734100A (en) 2000-08-07
MXPA01007031A (es) 2004-08-12
WO2000043028A9 (en) 2001-09-20
AU778001B2 (en) 2004-11-11
JP2002535282A (ja) 2002-10-22
EP1143996A2 (de) 2001-10-17
EP1143996A4 (de) 2002-04-24
US20030216312A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60128911D1 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE374021T1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties